Background and objectives
• It has been 15 years since the introduction of orphan medicinal product (OMP) legislation in the EU. Until 2014, one hundred and twelve orphan drugs had been approved in Europe 1 .
• Orphan drugs represent a particular challenge to payers due to the large unmet patient need, paucity of disease information and high per-patient costs 2 .
As of yet, there is no consensus on the most appropriate framework to assess the value of OMPs and to determine the price level at which they should be funded.
• The use of cost effectiveness analysis for assessing treatments for rare diseases has proven difficult given that rare disease treatments rarely meet traditional cost-effectiveness thresholds 3 . In addition, cost effectiveness analysis does not take into account other important factors such as unmet need and severity of the disease. Therefore, alternative frameworks for assessing value and determining pricing and reimbursement have been sought.
• The aim of this study was to summarise rare disease specific value assessment and pricing frameworks proposed in the literature.
Methods
• A systematic literature review was conducted using Medline and EMBASE databases and conference proceedings with an additional hand search for the period 2000 -2014 without geographic restriction.
• The search sought to identify papers that proposed specific frameworks for a) assessing the value of rare disease treatments or b) determining the price or reimbursement status of such drugs. Policy papers, commentaries and review articles were included. Clinical or economic studies of specific rare diseases and their treatments were excluded.
• The proposed frameworks were considered in respect to:
-Scope and purpose -Structure and methodology -Elements of value included.
Results
• The literature review identified 1,034 papers including publications, from conferences and an additional hand search. Of these, eleven papers were selected which included information on nine specific frameworks for assessing and/or pricing rare disease treatments. Figure 1 depicts a PRISMA flow diagram for the search.
• The nine frameworks are summarised in Table 1 . Three of the frameworks were country specific, three European focused, and three international or non-region specific. All were published since 2012.
Scope and purpose
• There is no consensus in the literature on what the scope of a rare disease assessment framework should encompass. Broadly, two key areas are considered in the frameworks: assessment of product value and mechanisms for determining price or funding status.
• Figure 2 depicts the scope of the nine frameworks identified in this review. Two of the frameworks (TVF, Sussex et al) focused only on the assessment of product value, without considering how value translates to a price or funding decision.
• Two frameworks (Fellows et al, Valverde et al) provided methods for determining the price and funding status of rare disease treatments, but without assessing product value.
• Five frameworks considered both value assessment and pricing/funding decision making, either together within the framework, or sequentially. For example, the Hughes-Wilson framework quantified value within a multi-criteria decision analysis (MCDA) framework, and then proposed that funding decisions should be determined by ranking all products according to their score and funding from the top down until the budget has been consumed.
Structure and methodology
• The most commonly proposed methodology for the value/pricing frameworks were a variant of MCDA (Table 1) . Authors highlighted the flexibility of such an approach to include a broader range of relevant factors that are pertinent to rare diseases.
• Only one framework (Sussex et al) included explicit preference weights derived from payers, patient representatives and clinical experts. In other frameworks weights were either not specified, assumed to be equally important across criteria, or, as in the case of Hughes-Wilson et al, country-specific preference weights were to be elicited via conjoint analysis. • Winquist et al described a framework in which seven elements were considered, but consecutively rather than concurrently, and with treatments required to 'pass' at each step before progressing to the next.
• Paulden et al proposed a framework that seeks to combine elements considered important by health economists (opportunity cost) with the greater breadth of considerations that are common in MCDA.
• Fellows et al and Valverde et al provided methods for determining the price and funding status of rare disease treatments, but without assessing product value.
Both frameworks proposed that price should be determined based upon a 'fair' rate of return on research investment.
Elements included in frameworks
• Figure 3 shows the elements included within each value framework, for all elements considered in more than one framework. Elements have been classified according to disease characteristics, treatment characteristics and economic and healthcare system aspects. Elements related to the former two occurred more frequently than the latter. • The elements that were considered most commonly across the frameworks were disease severity, unmet need (lack of other alternatives), clinical efficacy, magnitude of clinical benefit, societal benefit from treatment, quality of evidence and safety profile of treatment.
• Four frameworks included the cost or budget impact of the new treatment and three considered the amount of research effort and investment.
• Elements that existed in one framework only (and thus are not shown in Figure  4 ) include: feasibility of diagnosis/treatment, government policy objectives, manufacturing complexity, response rate, number of indications, and societal cost savings.
• Figure 4 presents a generalised depiction of the frameworks included in this review.
At least one of the following principal elements are included in every framework: -Value-based component (for example, clinical benefit of the new medicine relative to unmet need) -Non-value based component (factors that are separate from the fundamental value of the product, such as the amount of research investment) -Price/funding decision component (determines the price of a product or whether it should be funded).
Conclusions
• There is a need for a commonly accepted framework for making pricing and funding decisions for treatments for rare diseases.
• Currently, there is no consensus in the literature on the structure of such a framework nor the core elements for consideration.
• MCDA-type frameworks are most frequently proposed, and there is increasing convergence on the core value elements, but considerable difference on nonvalue elements.
• The issue that requires most consideration and further research is the process by which value is translated to price.
• There is considerable variation in terminology used by authors when describing rare disease frameworks, which complicates the task of reaching consensus. 
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